SEP 3, 2026 · PHASE 2/3 TRIAL
Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression
ClinicalTrials.gov
This is a Phase 2/3 trial registration with no posted results; it describes a planned intervention combining ketamine and behavioral activation for treatment-resistant depression but carries no efficacy or safety data.
Reported
Planned enrollment60
Primary outcome measureChange in MADRS from Baseline (Week 0) to e…
Ketamine dose0.5 mg/kg